3Eugene B. Heart Disease[ M]. 5版.北京:人民卫生出版社,2001:1728-1728.
4Task Force of the European Society of Cardiology and North Ameri- can Society of Pacing and Elcetrophycioigy. Heart rate Variability standards of measurement, Physiological interpetation and clinical use [ J ]. Circulation, 1996,93 : 1043 - 1065.
5Toyry JP, Nvs Konce, Mantysaain M J, et al. Occurrence, Predictors and clinical significance of autonomic neuropathy in NIDDM,ten year follow up from the diagnosis [ J ]. Diabetes, 1996,45 (3) :308 - 315.
6Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect[ J]. Diabetes Care, 2004, 27 (9) : 2253.
7Bermudez V, Final F, Par'a N, et al. PPAR - gamma ago- nists and their role in type 2 diabetes me|litus management [J]. Am J Ther, 2010, 1"t(3) : 274.
8Yu J, Zhang Z, Li Z, et d. Peroxisome prolifeator - activa- ted receptor - gamma( PPJLR gamma) agonist improves coro- nary artery endothelial function in diabetic patients with coro- nary artery disease[J]. J Int Med Res, 2010, 38(1) : 86.
9He W, Barak Y, Hevene A, el al. Adipose -specific perox- isome proliferator - activated receptor ',/knockout causes insu- lin resistance in fat and li'rer but not in muscle[J]. Pruc Nat! Acad Sei USA, 2003, 100(26) : 15712.
10Shang W, Yang Y, Jiang B, et al. Ginsenoside Rbl promotes adipogenesis in 3T3 L1 ceils by enhancing PPAR,2 and C/ EBPa gene expression[J] . Life Sci, 2007, 80(7) : 618.
